Transthyretin amyloid cardiomyopathy: clinical features and staging, indications for treatment and mortality. Rev. Fed. Arg. Cardiol. [Internet]. 2025 Jun. 30 [cited 2026 Oct. 5];54(2):111-7. Available from: https://www.revistafac.org.ar/ojs/index.php/revistafac/article/view/662